ESTROGEN-TREATMENT PREVENTS OSTEOPENIA AND DEPRESSES BONE TURNOVER IN OVARIECTOMIZED RATS
ESTROGEN-TREATMENT PREVENTS OSTEOPENIA AND DEPRESSES BONE TURNOVER IN OVARIECTOMIZED RATS
复制标题
DOI：
10.1210/endo-123-2-681
复制
发表时间：
1988-08-01
期刊：
影响因子：
4.8
通讯作者：
DANN, LM
中科院分区：
文献类型：
--
作者：
WRONSKI, TJ;CINTRON, M;DANN, LM
对雌性Sprague-Dawley大鼠进行双侧卵巢切除术（OVX）或假手术（对照）。卵巢切除（OVX）组和对照组大鼠每天注射低、中或高剂量的17 β-雌二醇（分别为10、25或50 μ g/kg BW）。另外一组OVX和对照大鼠每天单独注射溶剂。所有大鼠于OVX后35天处死，取其近端胫骨进行不脱钙骨形态计量学分析。相对于对照组大鼠，溶剂处理OVX大鼠的小梁骨体积显著降低（12.1% vs. 26.7%）。这种骨丢失与破骨细胞表面增加2倍和成骨细胞表面增加4倍有关。用荧光染料标记研究的骨形成速率在媒介物处理的OVX大鼠中也显著升高（0.111对0.026 μ m3/μ m2）。天）。相反，用三种剂量的雌二醇治疗OVX大鼠导致胫骨骨小梁体积正常化，骨吸收和形成的组织形态计量学指标下降。我们的研究结果表明，雌激素治疗提供了完整的保护，对骨质疏松症大鼠。保护机制包括雌激素抑制骨转换。这些发现与雌激素治疗对绝经后妇女骨骼的影响一致。
Female Sprague-Dawley rats were subjected to bilateral ovariectomy (OVX) or sham surgery (control). Groups of ovariectomized (OVX) and control rats were injected daily with low, medium, or high doses of 17.beta.-estradiol (10, 25, or 50 .mu.g/kg BW, respectively). An additional group of OVX and control rats was injected daily with vehicle alone. All rats were killed 35 days after OVX, and their proximal tibiae were processed undecalcified for quantitative bone histomorphometry. Trabecular bone volume was markedly reduced in vehicle-treated OVX rats relative to that in control rats (12.1% vs. 26.7%). This bone loss was associated with a 2-fold increase in osteoclast surface and a 4-fold increase in osteoblast surface. The bone formation rate,studied with fluorochrome labeling, was also significantly elevated in vehicle-treated OVX rats (0.111 vs. 0.026 .mu.m3/.mu.m2 .cntdot. day). In contrast, treatment of OVX rats with the three doses of estradiol resulted in normalization of tibial trabecular bone volume and a decline in histomorphometric indices of bone resorption and formation. Our results indicate that estrogen treatment provides complete protection against osteopenia in OVX rats. The protective mechanism involves estrogenic suppression of bone turnover. These findings are consistent with the skeletal effects of estrogen therapy in postmenopausal women.